Palexia Retard (Tapentadol Hydrochloride)

Tapentadol Hydrochloride, the active ingredient in Palexia Retard, is an opioid analgesic presented as an extended‑release tablet for oral use. It is indicated for the management of moderate to severe acute pain, chronic pain and cancer‑related pain in adult patients. GNH USA supplies Palexia Retard as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Palexia Retard is an opioid analgesic used in the management of pain conditions across several clinical pathways. - Acute pain: Provides rapid relief of moderate to severe pain following surgery or injury. - Chronic non‑cancer pain: Helps control persistent pain that has not responded adequately to non‑opioid therapies. - Cancer pain: Alleviates moderate to severe pain associated with malignant disease and its treatment.

Adverse reactions to Palexia Retard may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Constipation: reduced bowel movements. - Dizziness: feeling light‑headed or unsteady. - Somnolence: increased sleepiness. - Headache: mild to moderate head pain. - Dry mouth: reduced salivation.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing. - Severe hypotension: marked drop in blood pressure. - Seizures: convulsive episodes. - Opioid use disorder: risk of dependence or addiction. - Anaphylaxis: severe allergic reaction with rash, swelling or airway compromise.

When prescribing Palexia Retard, clinicians should consider several safety aspects. - Assess pain severity and opioid tolerance before initiating therapy. - Monitor for signs of respiratory depression, especially during dose titration. - Evaluate hepatic and renal function, adjusting dose if impairment is present. - Avoid concomitant use with other central nervous system depressants when possible. - Educate patients on proper use, risks of dependence and safe storage. - Store at ambient temperature: keep tablets in original packaging, protect from moisture and heat.

Palexia Retard can interact with a range of medicines; awareness of interaction severity guides clinical management.

Major Interactions (Avoid): - CNS depressants: combined use may cause profound sedation or respiratory depression. - MAO inhibitors: may precipitate hypertensive crisis or serotonin syndrome. - CYP2D6 inhibitors: can increase tapentadol plasma levels, raising toxicity risk.

Moderate Interactions (Monitor Closely): - Serotonergic agents (SSRIs, SNRIs): may increase risk of serotonin syndrome. - Benzodiazepines: additive sedative effects require dose adjustment. - Antihistamines: may enhance central nervous system depression. - Diuretics: can potentiate hypotensive effects.